Cibus (CBUS) Current Deferred Revenue (2016 - 2026)
Cibus (CBUS) posted Current Deferred Revenue of $536000.0 for Q4 2025, down 42.49% sequentially from $932000.0 in Q3 2025, and down 42.49% YoY from $932000.0 in Q4 2024.
Cibus (CBUS) Current Deferred Revenue (2016 - 2026) Analysis & Trends
Cibus has reported Current Deferred Revenue for 7 years, with the latest figure at $536000.0 in Q4 2025.
- Quarterly Current Deferred Revenue fell 42.49% year-over-year to $536000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $536000.0 (down 42.49% YoY) and the FY2025 annual result came in at $536000.0, down 42.49% from the prior year.
- Current Deferred Revenue retreated to $536000.0 in Q4 2025 per CBUS's latest filing, from $932000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $1.6 million in Q3 2023 and troughed at $107000.0 in Q4 2022.
- A 4-year average of $1.1 million and a median of $1.0 million in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue jumped 1030.84% in 2023, then plunged 43.44% in 2025.
- Over 4 years, Current Deferred Revenue stood at $107000.0 in 2022, then surged by 1030.84% to $1.2 million in 2023, then dropped by 22.98% to $932000.0 in 2024, then sank by 42.49% to $536000.0 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $536000.0, $932000.0, and $918000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Cibus | 131.25 Mn | 110.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 627,000.00 |
| Dec 31, 2025 | 536,000.00 |
| Sep 30, 2025 | 932,000.00 |
| Jun 30, 2025 | 918,000.00 |
| Mar 31, 2025 | 863,000.00 |
| Dec 31, 2024 | 932,000.00 |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Dec 31, 2022 | 107,000.00 |
| Sep 30, 2018 | 7,000.00 |
| Jun 30, 2018 | 9,000.00 |
| Mar 31, 2018 | 43,000.00 |
| Dec 31, 2017 | 43,000.00 |
| Sep 30, 2017 | 78,000.00 |
| Jun 30, 2017 | 109,000.00 |
| Dec 31, 2016 | 101,000.00 |